nd ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. Brivanib alaninate BMS-582664 Haematologica. 2008, 93:662 9. 78. Schellens JH, Boss D, Witteveen PO, et al. Phase I and pharmacological study of the novel aurora kinase inhibitor AZD1152. J Clin Oncol. 2006, 24 abstr 3008. 79. Lowenberg B, Rousselot P, Martinelli G, et al. Phase I/II study to assess the safety and efficacy of the aurora B kinase inhibitor, AZD1152, in patients with advanced acute myeloid leukemia. Blood . 2009, 114 abstr 2080. 80. Guo J, Anderson MG, Tapang P, et al. Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD 1152. Pharmacogenomics J. 2009, 9:90 102. 81. Anderson K, Lai Z, McDonald OB, et al.
GSK1363089 Biochemical characterization of GSK1070916, a potent and selective inhibitor of aurora B and aurora C kinases with an extremely long residence time. Biochem J. 2009, 420:259 65. 82. Hardwicke MA, Oleykowski CA, Plant R, et al. GSK1070916, a potent aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Mol Cancer Ther. 2009, 8:1808 17. 83. Mahadevan D, Beeck S. Aurora kinase targeted therapeutics in oncology: past, present and future. Expert Opin Drug Discov. 2007, 2:1011 1026. 84. Gadea BB, Ruderman JV. Aurora kinase inhibitor ZM447439 blocks chromosome induced spindle assembly, the completion of chromosome condensations, and the establishment of the spindle integrity checkpoint in Xenopus egg extracts. Mol Biol Cell. 2005, 16:1305 18. 85. Ikezoe T, Nichioka C, Tasaka T, et al.
ZM447439, a novel aurora kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells. Blood . 2006, 108 abstr 1990. 86. Georgieva I, Koychev D, Wang Y, et al. ZM447439, a novel promising aurora kinase inhibitor, provokes antiproliferative and proapoptotic effects alone and in combination with bio and chemotherapeutic agents in gastroenteropancreatic neuroendocrine tumor cell lines. Neuroendocrinology. 2010, 91:121 30. 87. Vidarsdottir L, Bodvarsdottir S, Ogmundsdottir H, Eyfjord J. Targeting aurora kinases in BRCA2 mutated breast cell lines. Proc Am Assoc Cancer Res. 2008, 49 abstr 2395. 88. Crispi S, Fagliarone C, Biroccio A, et al. Antiproliferative effect of aurora kinase targeting in mesothelioma. Lung Cancer. 2010 article in press. 10.1016/j.lungcan.2010.03.2005 Green et al.
Page 18 Expert Opin Drug Discov. Author manuscript, available in PMC 2012 March 1. NIH PA Author Manuscript NIH PA Author Manuscript NIH PA Author Manuscript 89. Emanuel S, Rugg CA, Gruninger RH, et al. The in vitro and in vivo effects of JNJ 7706621: A dual inhibitor of cyclin dependent kinases and aurora kinases. Cancer Res. 2005, 65:9038 46. 90. Howard S, Berdini V, Boulstridge JA, et al. Fragment based discovery of the pyrazol 4 yl urea , a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem. 2009, 52:379 88. 91. Curry J, Angove H, Fazal L, et al. Aurora B kinase inhibition in mitosis: strategies for optimizing the use of aurora kinase inhibitors such as AT9283. Cell Cycle. 2009, 8:1921 9. 92. Dawson MA, Curry JE, Barber K, et al.
AT9283, a potent inhibitor of the aurora kinases and JAK2, has therapeutic potential in myeloproliferative disorders. Br J Haematol. 2010, 150:46 57. 93. Squires M, Reule M, Curry J, et al. AT9283, a potent inhibitor of BCR Abl T315I, is active in CML models. Proc Am Assoc Cancer Res. 2008, 49 abstr 2820. 94. Goodall J, Squires MS, Lock V, et al. Outcome of aurora kinase inhibition of acute myeloid leukemia by AT9283 is dependent upon the presence or absence of mutations in type 1 oncogenic kinase signaling pathways. Blood . 2008, 112 abstr 1613. 95. Lotfi S, Jayanthan A, Lewis VA, et al. AT9283, a novel aurora kinase/JAK2 inhibitor, demonstrates activity against refractory infant leukemia cells: studies on growth inhibition, biological correlates, drug synergy and effects on leukemia stem like cells. Bloo
Other articles you might like;
- Vargatef BIBF1120 is ineffective or induced side effects
- LY2157299 is a specificity t for a target with a KM ATP as the average of the plate
- R788 Fostamatinib is particularly important
- DMXAA is 18 and 20 h time More frequently than the mRNA Aurkc GM and Level II are met
- BMS 777607 protect load beautiful to monitor progression